Study Purpose:
The purpose of the study is to compare the relative sensitivity of 3 outcomes measures in measuring disease progression in patients with ALS over time.Study Status:
Not recruiting
Disease:
Amyotrophic Lateral Sclerosis (ALS) , Familial ALS , Sporadic ALS
Study Type:
Observational
Type of Intervention:
N/A
Intervention Name:
N/A
Placebo:
N/A
Phase:
N/A
Study Chair(s)/Principal Investigator(s):
Patricia L. Andres, DPT, MS (Massachusetts General Hospital)
Clinicaltrials.gov ID:
Neals Affiliated?
Yes
Coordinating Center Contact Information
Massachusetts General Hospital
Patricia Andres / email hidden; JavaScript is required / (617) 724-8995
1256 Bigelow NCRI 55 Fruit Street
Boston, Massachusetts, 02114 United States
Full Study Summary:
Four sites will participate in data collection for this study and will enroll approximately 20-30 subjects per site. Subjects will be tested every 1 to 4 months for up to two years. Subjects will be tested at each visit using ATLIS, ALSFRS-R questionnaire and slow vital capacity testing.
Study Sponsor:
The ALS Association
Participant Duration:
Total time enrolled in study is up to 2 years. Subjects will spend about 45 minutes at each visit to the clinic (every 1 to 4 months) to complete study procedures.
Estimated Enrollment:
100
Estimated Study Start Date:
06 / 30 / 2013
Estimated Study Completion Date:
11 / 30 / 2014
Posting Last Modified Date:
12 / 31 / 2015
Date Study Added to neals.org:
07 / 02 / 2013
Minimum Age:
18
Inclusion criteria:• Subjects 18 years or older diagnosed with clinically possible, laboratory supported probable, probable or clinically definite ALS according to the World Federation of Neurology Revised El Escorial Criteria.
• Capable of providing informed consent and complying with trial procedures.
• Active movement of at least two limbs at the time of study entry
• Intend to routinely attend clinic for neurological care at the clinical site
Exclusion criteria:
• Patients, judged by the site clinical investigator to have medical conditions that may limit their ability to safely exert maximal force using the muscles in their arms and legs will be excluded from this study (e.g. unstable hypertension, significant cardiac disease, significant musculoskeletal disorders, or other medical conditions).
Cedars-Sinai Medical Center
Peggy Allred, DPT / (424) 315-2694 / email hidden; JavaScript is required
Los Angeles, California
90048
United States
University of Kentucky
Tony English, PT, PhD / (859) 323-1100 x80834 / email hidden; JavaScript is required
Lexington, Kentucky
40536
United States
Massachusetts General Hospital
Christina Dheel / 617-643-6252 / email hidden; JavaScript is required
Boston, Massachusetts
02114
United States
Washington University School of Medicine
Catherine Siener, PT, MHS / 314-362-8651 / email hidden; JavaScript is required
St. Louis, Missouri
63110
United States
Hershey Medical Center
Beth Stephens / (717) 531-0003 x 283395# / email hidden; JavaScript is required
Hershey, Pennsylvania
17033
United States